Novo Nordisk A/S NVO DK:NOVO.B said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease. The Denmark-based biotechnology company said the drug is currently in a Phase 3 trial for uncontrolled hypertension and advanced chronic kidney disease. “This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said…
Read the full article here
